Arrien Pharmaceuticals is focused on the drug discovery and development of innovative targeted therapeutics for the treatment of human cancers, autoimmune and neurodegenerative diseases.

Our Small Molecule I-O Programs - Stages of Development

Our Non-Oncology Programs - Available for Partnering/Licensing

Our Partnered Program

Clinical Program
Inhibitor of ROR-γt (Psoriasis, RA and MS)
Partner: Worldwide exclusive license granted to Boston Pharmaceuticals in 2017.

Mechanism of Action: The nuclear hormone receptor retinoic acid-related orphan receptor gamma t (ROR-γt) is a transcription factor (TF) specific to TH17 cells that produce interleukin (IL)-17 and have been implicated in a wide range of autoimmunity.

ARN-3261 (Now called GRN300)
Inhibitor of SIK2 (Salt Inducible Kinase 2)
Phase 1a/1b clinical trials in patients with recurrent ovarian, primary peritoneal, fallopian tube, other solid tumors will be initiated in Q1 2021.

The pipeline above provides the most advanced programs in the areas of Oncology, Autoimmune, CNS/Neurodegenerative diseases and stages of drug development process.